Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis

John B. Hagan; Kathleen R. Bartemes; Hirohito Kita; Eric A. Ottesen; Kwablah Awadzi; Thomas B. Nutman; Gerald J. Gleich

doi:10.1093/infdis/173.5.1277

Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis

John B. Hagan, Kathleen R. Bartemes, Hirohito Kita, Eric A. Ottesen, Kwablah Awadzi, Thomas B. Nutman, Gerald J. Gleich

Allergic Diseases

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.

Original language	English (US)
Pages (from-to)	1277-1280
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	173
Issue number	5
DOIs	https://doi.org/10.1093/infdis/173.5.1277
State	Published - 1996

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/173.5.1277

Cite this

@article{800e246611ec4456aa75260956047371,

title = "Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis",

abstract = "The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.",

author = "Hagan, {John B.} and Bartemes, {Kathleen R.} and Hirohito Kita and Ottesen, {Eric A.} and Kwablah Awadzi and Nutman, {Thomas B.} and Gleich, {Gerald J.}",

note = "Funding Information: Received 14 August 1995; revised 2 January 1996. Presented: annual meeting of the American Academy of Allergy and Immunology in Anaheim, California, 5-9 March 1994. Informed consent was obtained from all patients, and the study was performed under protocols approved by the National Institute of Allergy and Infectious Diseases and the Ghanaian Ministry of Health Grant support: National Institutes ofHealth (AI-15231, AI-34486, AI-34577) and Mayo Foundation. Reprints or correspondence: Dr. Gerald 1. Gleich, Dept. of Immunology, Mayo Clinic, Rochester, MN 55905. *Currentaffiliation: DivisionofControlofTropicalDiseases,WorldHealth Organization, Geneva, Switzerland.",

year = "1996",

doi = "10.1093/infdis/173.5.1277",

language = "English (US)",

volume = "173",

pages = "1277--1280",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis

AU - Hagan, John B.

AU - Bartemes, Kathleen R.

AU - Kita, Hirohito

AU - Ottesen, Eric A.

AU - Awadzi, Kwablah

AU - Nutman, Thomas B.

AU - Gleich, Gerald J.

N1 - Funding Information: Received 14 August 1995; revised 2 January 1996. Presented: annual meeting of the American Academy of Allergy and Immunology in Anaheim, California, 5-9 March 1994. Informed consent was obtained from all patients, and the study was performed under protocols approved by the National Institute of Allergy and Infectious Diseases and the Ghanaian Ministry of Health Grant support: National Institutes ofHealth (AI-15231, AI-34486, AI-34577) and Mayo Foundation. Reprints or correspondence: Dr. Gerald 1. Gleich, Dept. of Immunology, Mayo Clinic, Rochester, MN 55905. *Currentaffiliation: DivisionofControlofTropicalDiseases,WorldHealth Organization, Geneva, Switzerland.

PY - 1996

Y1 - 1996

N2 - The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.

AB - The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.

UR - http://www.scopus.com/inward/record.url?scp=0030015014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030015014&partnerID=8YFLogxK

U2 - 10.1093/infdis/173.5.1277

DO - 10.1093/infdis/173.5.1277

M3 - Article

C2 - 8627086

AN - SCOPUS:0030015014

SN - 0022-1899

VL - 173

SP - 1277

EP - 1280

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this